Media stories about Aytu Bioscience (NASDAQ:AYTU) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aytu Bioscience earned a news impact score of 0.25 on Accern’s scale. Accern also gave news articles about the company an impact score of 47.7364246013842 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Aytu Bioscience (AYTU) traded down $0.26 during trading hours on Tuesday, reaching $2.80. 136,700 shares of the company traded hands, compared to its average volume of 7,108. Aytu Bioscience has a 52-week low of $2.35 and a 52-week high of $26.80.
Aytu Bioscience (NASDAQ:AYTU) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($1.76) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($7.60) by $5.84. Aytu Bioscience had a negative net margin of 807.57% and a negative return on equity of 432.48%. The firm had revenue of $1.08 million during the quarter.
Aytu BioScience, Inc is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer.
Receive News & Ratings for Aytu Bioscience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience Inc and related companies with MarketBeat.com's FREE daily email newsletter.